Johan Wäborg, General Manager Nordic countries at Actelion, shares the importance of Sweden for the group due to its world-class healthcare system and community of experts as well as its national quality and health registries which make the country an ideal environment for early launches and follow-up of treatment outcomes. He also talks about the synergies between Actelion and J&J which share the goal of improving the lives of people suffering from cardiopulmonary diseases through the introduction of improved diagnostic methods and new treatments.
Historically, Sweden has been an early adopter of orphan drugs. In terms of market access, what sets Sweden apart is its value-based system of approval and reimbursement of new medicines.
